Four updated COVID-19 vaccines targeting the XFG variant were approved for the 2026–27 season on August 27, making every adult 65 or older eligible under federal labeling while limiting younger recipients to those with a condition that raises their risk of severe disease. The approvals cover Moderna’s Spikevax and mNexspike, Pfizer-BioNTech’s Comirnaty and the protein-based Nuvaxovid sold by Sanofi, according to Reuters. The products are designed to replace last season’s LP.8.1 formula as manufacturers begin fall distribution.

The Food and Drug Administration’s action completes the regulatory step, but it does not settle who will be advised to receive a dose or how uniformly it will be covered. Federal recommendations normally pass through the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices, or ACIP. A federal court froze the work of members appointed by Health Secretary Robert F. Kennedy Jr., leaving the CDC without its customary mechanism for updating guidance.

The result is an unusual split between product availability and public-health policy. Pharmacies and clinics can administer the approved vaccines within their labels, and Pfizer said Comirnaty shipments would begin immediately. Yet patients, clinicians and health plans enter the season without a new ACIP recommendation for the XFG formula. Federal law links many no-cost coverage requirements to ACIP recommendations, although major insurers have promised continuity through 2026.

Why the Formula Changed

XFG is a descendant of the JN.1 lineage that has circulated since late 2023. The FDA’s vaccine advisers voted in May to prefer a monovalent XFG component after reviewing genomic surveillance, antigenic data, vaccine effectiveness, immune responses and production timelines. The agency’s formula guidance said an XFG-matched shot offered the closest fit to viruses then circulating in the United States.

Updating the antigen is intended to reduce the distance between the vaccine strain and variants people are likely to encounter. It does not mean the previous formula stopped working, nor does a laboratory immune response establish how much illness the new shots will prevent. The process relies on accumulated evidence for the platforms plus manufacturing and nonclinical evidence for the revised antigen.

Pfizer and BioNTech reported that their XFG-adapted formula produced strong immune responses in nonclinical testing against XFG, XFG.1.1, NB.1.8.1 and several newer lineages. The companies’ announcement also said the product would reach pharmacies, hospitals and clinics within days. Those data supported the manufacturing change, but estimates of real-world protection will require observation after vaccination begins and will depend on how the virus evolves.

Eligibility Differs by Product

All four products are approved for people 65 and older and for younger people with at least one underlying condition associated with severe COVID-19. The lower age boundary varies. The FDA’s Spikevax label reaches children from 6 months through age 64 in the high-risk group, while Comirnaty begins at age 5. Moderna’s mNexspike and Sanofi-Novavax’s Nuvaxovid begin at age 12 for high-risk recipients.

That structure continues the narrower eligibility framework adopted in 2025, when the FDA moved away from a label covering nearly everyone at least 6 months old. For people under 65, the key regulatory question is no longer age alone but whether a clinical condition places them at elevated risk. The FDA labeling does not create one simple public checklist at the pharmacy counter, so providers and patients may need to document or discuss qualifying conditions.

The products also differ technologically. Comirnaty, Spikevax and mNexspike use messenger RNA, while Nuvaxovid uses a recombinant protein and an adjuvant. That gives eligible people a non-mRNA option, although availability may differ because the protein vaccine takes longer to manufacture. Approval means the FDA concluded each product’s benefits outweigh its known risks for the labeled population; it does not make the products identical.

Evidence Supports Added Protection

The strongest evidence for a seasonal dose comes from prior updated formulas rather than the newly revised shots, which have not yet accumulated real-world outcome data. A peer-reviewed U.S. study of the 2025–26 LP.8.1 formula estimated 50 percent effectiveness against COVID-related emergency or urgent-care encounters and 55 percent against hospitalization compared with not receiving that season’s dose. Among adults 65 and older, effectiveness was estimated at 48 percent against emergency or urgent-care visits and 53 percent against hospitalization, according to the JAMA study.

Those figures describe relative risk reduction during a defined early-season period, not the proportion of all recipients who will avoid illness. The study used a test-negative observational design, which compares vaccination among people who seek care and test positive with those who test negative. Researchers adjust for measured differences, but unmeasured behavior, prior infection and access to care can still influence results. Protection also wanes, and a new variant could change the match between the vaccine and circulating virus.

The FDA’s choice of XFG therefore reflects a probabilistic judgment: updating toward the dominant lineage should improve immune recognition, while the platform and prior-season evidence support an expectation of renewed protection against medically attended disease. It does not prove that the 2026–27 formula will deliver the same effectiveness estimates. Postauthorization surveillance will need to measure infections, emergency visits, hospitalizations and rare adverse events separately, rather than treating antibody levels as a clinical endpoint.

Activity Is Rising From a Low Level

The approvals arrive as national respiratory illness remains low but COVID-19 indicators are increasing. The CDC’s respiratory dashboard said acute respiratory illness causing people to seek care was very low as of August 21, while national and regional COVID-19 activity was rising. Its wastewater system is useful because it can detect community spread before clinical visits and includes infections in people without symptoms, although recent estimates can change as sites report additional data.

A low national level does not eliminate the individual stakes for older adults, immunocompromised people and those with chronic conditions. COVID-19 continues to produce hospitalizations and deaths, and risk is concentrated unevenly by age, immune status and underlying illness. That is why the regulatory labels provide universal eligibility at 65 while using risk-based eligibility below that threshold. The timing of a seasonal dose may also depend on prior vaccination, recent infection and an individual’s risk of exposure or severe outcomes.

The public-health rationale is more targeted than the early pandemic campaign. The goal is not to prevent every infection or halt transmission. It is to restore protection that declines over time and improve the match to circulating strains, with the largest expected value among people most likely to develop severe disease.

Coverage Remains the Practical Test

FDA approval permits use; CDC recommendations ordinarily determine how the vaccines are incorporated into national schedules and influence payment. Under federal preventive-services rules, most non-grandfathered private plans must cover ACIP-recommended vaccines without cost sharing when provided in network. The Centers for Medicare and Medicaid Services also says individual recommendations can qualify when a clinician prescribes vaccination consistently with ACIP guidance, according to its coverage guidance.

The court order has made the sequence less certain. In April, Reuters reported that the ruling froze ACIP’s work and restored the earlier schedule while leaving no functioning panel to evaluate newly approved or annually updated products. The insurance trade group AHIP pledged that participating plans would continue covering vaccines recommended as of September 1, 2025, without cost sharing through the end of 2026. That commitment reduces near-term risk for many insured patients but does not replace a current federal recommendation or guarantee identical handling by every payer and program.

Clinicians and patients will therefore need to distinguish three questions that usually move together: whether a vaccine is licensed, whether federal advisers recommend it and whether a particular plan pays without cost sharing. The first is now answered for the XFG products. The second remains unresolved for the 2026–27 formula, and the third may depend on existing commitments, plan rules and the recipient’s eligibility.

The approvals ensure that matched vaccines can begin reaching the U.S. market before autumn respiratory activity accelerates. What they do not provide is outcome evidence for the XFG formula or a fully updated national pathway for recommendation and coverage. The next decisive developments will be the CDC’s clinical guidance, the operating status of ACIP, payer instructions and the first real-world estimates of effectiveness against urgent care, hospitalization and death.